Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Shareholder Meeting (November 2025)
24 slides from Oncosil Medical's shareholder meeting presentation, Nov 19, 2025
Slide 1: Chairman's Address to 2025 Annual General Meeting
ASX Announcement 19 November 2025 Chairman’s Address to 2025 Annual General Meeting Sydney, Australia – 19 November 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced
Slide 2: Chairman's Address (continued)
advanced healthcare environments. We expect to commence the clinical trial under the G-BA in the first half of calendar year 2026 and hence the commencement of meaningful revenues. We appreciate investors patience with this initiative, which has taken longer than expected, however it will mean a sig
Slide 3: Chairman's Address (continued)
We undertook several capital raises during FY25 totalling more than $14 million, and as at 30 September 2025, being the most recent quarter, held $5.9 million in cash and cash equivalents. We thank all investors for their support in those capital raises, which allows the company to continue to inves
Slide 4: Authorisation & Additional Information
Authorisation & Additional Information This announcement was authorised by the Board of Directors of OncoSil Medical Limited. For further information, please contact: Mr. Nigel Lange Mr. Tim Luscombe & Mr. David Wood Ms. Julia Maguire CEO & Managing Director Joint Company Secretaries The Capital Net
Slide 5: OncoSil: Intratumoural placement of 32P for locally advanced pancreatic cancer
For personal use only OncoSil Intratumoural placement of 32P for locally advanced pancreatic cancer Nigel Lange, 19 November 2025 1
Slide 6: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 7: Corporate Overview
Corporate Overview OncoSil Medical | 13 November 2025 OncoSil Medical Major Shareholders | 13 November 2025 Health Care – Pharmaceuticals, Washington H. Soul Pattinson 18.18% GICS: Biotechnology & Life Sciences (Life (Pengana Capital Group Limited) For personal use only Sciences Tools & Services) St
Slide 8: Experienced Board and Management
Experienced Board and Management Depth in Interventional Oncology and Nuclear Medicine Commercialisation For personal use only Dr Thomas Nigel Lel Duthy Lange Smits Non-executive Managing Director Non-executive Chairman & CEO Director Executive Director 20+ years of experience across Award-winning e
Slide 9: Recent Achievements
Recent Achievements For personal use only MDR Approval Innovation funding German Federal Joint Engagement with US FDA received with lifting approval (NUB status 1) Committee (G-BA) tender on Distal of post-market across 120 German in final stages for Cholangiocarcinoma restrictions Hospitals appoint
Slide 10: Executive Summary
Executive Summary • OncoSil Medical is commercialising the OncoSil device, an implanted device (brachytherapy) delivering targeted radiation (32P) to pancreatic tumours Commercialising For personal use only • OncoSil device is now approved for sale in over 34 countries via CE Mark targeted radiother
Slide 11: Executive Summary: Significant achievements over CY25
Executive Summary • Received MDR Approval which includes the removal of all existing post-market restrictions (OSPREY registry) • Patient recruitment completed for PANCOSIL study and preliminary data presented at CIRSE 2025 Congress (a groundbreaking For personal use only delivery method for OncoSil
Slide 12: Pancreatic Cancer Prognosis has Remained Unchanged for Years
Pancreatic Cancer Prognosis has Remained Unchanged for 40 Years1 Changes in survival, 1971-72 to 2010-11 0% 25% 50% 75% 100% For personal use only All Cancers Incidence Survival rates are very poor: Testis Malignant Melanoma • 8.5 months overall median survival Prostate Hodgkin Lymphoma • <12% reach
Slide 13: Pancreatic Cancer Stage at Diagnosis
Pancreatic Cancer Stage at Diagnosis Surgical resection remains the only potentially curative treatment for pancreatic cancer1 RESECTABLE LOCALLY ADVANCED METASTATIC For personal use only % of patients at diagnosis 15% 30% 55% Surgical resection with Palliative therapies Palliative therapies curativ
Slide 14: OncoSil Device
OncoSil Device Driving increased resection rates, downstaging, survival benefits and quality of life For personal use only OncoSil is intended for the treatment of OncoSil is currently implanted Percutaneous delivery is transformational locally advanced unresectable pancreatic directly into a pancre
Slide 15: Growing Body of Evidence
Growing Body of Evidence 4 clinical studies supporting commercialisation demonstrate efficacy, safety and tolerability in LAPC Unresectable LAPC Unresectable Locally Advanced Pancreatic Cancer (LAPC) Metastatic PDAC or Borderline-Resectable LAPC For personal use only Study PanCO Study 1 OncoPaC-1 St
Slide 16: Significant Commercial Opportunity
Significant Commercial Opportunity Existing Priority Markets Pancreatic Cancer Locally Advanced Market Opportunity Target Market Incidence p.a.1 Pancreatic Cancer2 (A$m)3 UK 11,852 3,556 138 For personal use only Spain 9,282 2,785 108 OncoSil device remains at the early- Italy 16,111 4,833 188 stage
Slide 17: Accelerating Commercialisation
Accelerating Commercialisation Enhancing market access via label extension For personal use only Program Description Key Milestones Commercial Impact • Patient recruitment completed Feasibility and safety of CT-guided percutaneous Accelerates market penetration with • Initial results were presented
Slide 18: Unlocking Market Potential in Germany
Unlocking Market Potential in Germany Commercial significance of G-BA Trial and beyond Expecting first treatment in G-BA For personal use only trial in H1 CY26 Opportunity to open 20 additional sites before start of G-BA trial First patient treatment at Germany in Oct-25 (outside of trial) Tender pr
Slide 19: Unlocking Market Potential in Germany
Unlocking Market Potential in Germany Commercial significance of G-BA Trial and beyond Complex Pancreatic Surgeries in 2024 For personal use only 700 583 600 500 400 300 212 171 150 148 148 143 142 142 139 200 126 124 113 102 98 96 93 92 82 82 100 0 The top 50 German pancreatic cancer centers perfor
Slide 20: Unlocking Market Potential in Europe
Unlocking Market Potential in Europe Accelerating growth in existing territories For personal use only Country Key Milestones Commercial Importance • OncoSil available in 11 hospitals • Largest revenue-contributing market Spain • 6 hospitals routinely ordering and treating with OncoSil • Strong refe
Slide 21: Outlook
Outlook Commercial ramp up with upside expected from new market access initiatives For personal use only Unit volumes are expected to ramp up materially following onboarding activities in existing initial markets in CY26 Volumes in existing markets are expected to underpin growth from market entry e
Slide 22: Upcoming Milestones
Upcoming Milestones Significant catalysts over the next 12 months Regulatory submission for For personal use only Regulatory submission for Results of label expansion to include percutaneous application First OncoSil TRIPP-FFX trial FOLFIRINOX treatment at France Finalisation of GBA Label expansion
Slide 23: Technology & Innovation
Technology & Innovation Macquarie Cyclotek site For personal use only Macquarie Operations in process of final validation (95% complete) – completion target Q1 CY26 New Target from ANSTO being used in the validation with more capacity, quality and versatility. Quartz Ampoule from Mo-Sci fully im
Slide 24: Nigel Lange, CEO & Managing Director
For personal use only Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Learn more about OncoSil Medical: • Website • ASX announcements • LinkedIn
OncoSil Medical — Shareholder Meeting (November 2025) on 6ix